Scientist – Assay Development
About the job
- A Ph.D. in Biochemistry or Molecular Biology, or an MS degree with a minimum of three years of industrial experience.
- Ability to manage projects with a positive “can-do” attitude.
- Knowledge of emerging reagents, immunoassay technologies, biomarker discovery, assay prototyping, performance optimization, and control system design.
- Proficiency in data management is highly beneficial.
- Good communication skills are required to work effectively within a multidisciplinary team environment.
- Good command of English listening, speaking, reading, and writing.
- Design and execute experiments to detect new biomarkers.
- Carry out data analysis, interpret and evaluate results, and ensure robustness, accuracy, precision, specificity, and sensitivity; use discretion to complete tasks.
- Collaborate with cross-functional teams to ensure the timely and accurate completion of deliverables.
- Solve problems through research of multiple alternatives.
- Proactively identify opportunities to enhance product functionality and process efficiency, contributing to continuous improvement.
- Provide technical guidance and training to junior team members.
- Develop and document technology and product requirements, protocols, and work instructions, ensuring clarity and compliance with industry standards.
- Experience in developing multiplex assays or antibody pair development.
About the company
Alamar Biosciences provides access to a high-throughput proteomics platform built around NULISA™, a sensitive method for detecting and measuring proteins, and the ARGO™ system, a fully automated workflow for profiling hundreds to thousands of protein targets. It serves researchers and clinicians who need to detect low-abundance protein biomarkers with multiplexing capabilities, paying for use of the technology and platform rather than selling a standalone instrument. The core difference from competitors is its combination of ultra-sensitive protein detection across a wide range and an automated, scalable workflow that reduces the need for specialized expertise, enabling single-target or large-scale multiplex experiments. The company’s goal is to advance understanding of protein roles in health and disease, enabling early disease detection and the development of new diagnostics and treatments through repeatable, high-throughput proteomics.
Company Size
201-500
Company Stage
IPO
Headquarters
Hayward, California
Founded
2018
Get referred to Alamar Biosciences
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 82% to $29.4 million; consumables jumped 147%.
- Alamar guided 2026 revenue to $116 million-$120 million and expects 100 more instruments.
- September 15, 2026 Morgan Stanley exposure and analyst upgrades lifted shares near $38.54.
What critics are saying
- Olink's Delaware suit and Federal Circuit appeal threaten NULISA sales and future IP freedom.
- Without FDA authorization for ARGO HT DX, Alamar stays trapped in research markets.
- Academia and biopharma funding swings hit consumables pull-through fast, reversing August 2026 growth.
What makes Alamar Biosciences unique
- NULISA detects ultra-low proteins with ARGO HT automation and multiplexing across blood samples.
- August 2026 AD Data Initiative deal expands to 86,000 samples, validating platform demand.
- July 2026 Immune 340 and eMTBR-Tau broaden Alamar's menu beyond Alzheimer’s research.
Help us improve and share your feedback! Did you find this helpful?
Benefits
401(k) Company Match
401(k) Retirement Plan
Performance Bonus
Company Equity
Growth & Insights and Company News
6 month growth
1%1 year growth
0%2 year growth
2%Alamar Biosciences has appointed Bob Ragusa, former CEO of GRAIL and ex-chief operations officer of Illumina, to its board of directors. Ragusa brings over 20 years of experience in genomics, diagnostics and biotech. The precision proteomics company also expanded its leadership team with two appointments. John Brottem joins as general counsel, bringing legal experience from Outset Medical and Omnicell. Amelia Merrill becomes chief people officer, having previously held senior HR roles at Guardant Health, RMS and Outset Medical. Alamar's NULISA platform detects protein biomarkers at low concentrations with high sensitivity. The company's technology aims to enable early disease detection through multi-marker protein testing. Founder and CEO Yuling Luo said Ragusa's experience scaling platform companies would prove valuable as Alamar advances its mission.
Alamar Biosciences shares soar 15.90% near 52-week high amid growing proteomics analyst and investor buzz. The precision proteomics company's shares rose to $37.10 amid growing attention around its technology platform, commercial partnerships and planned path towards clinical diagnostic use. Published 09/19/26 AT 2:40 AM AEST FREMONT, Calif. - Shares of Alamar Biosciences Inc. surged 15.90% to $37.10 in Thursday trading, adding $5.09, pushing the precision proteomics company's stock close to its 52-week high as investor interest continues building following a string of recent analyst upgrades, strategic partnerships and appearances at major healthcare investor conferences. The rally lifts Alamar shares near the top of a 52-week trading range that has spanned from $17.00, the price at which the company priced its initial public offering in April, to a high of $38.54. Alamar debuted on the Nasdaq on April 20, with shares jumping 33% on their first day of trading and valuing the precision protein biomarker detection company at approximately $1.53 billion at the time. The company's IPO raised roughly $219.9 million in gross proceeds after pricing 12.9 million shares, including the full exercise of the underwriters' option, at $17 per share, the high end of its marketed range. Alamar's stock has continued to draw attention from Wall Street analysts in the months since its public debut. Leerink initiated coverage of the company with an Outperform rating and a $35 price target, with the firm's thesis centered on what it described as Alamar's differentiated, highly automated ARGO HT instrument and its underlying NULISA technology platform. Stifel more recently raised its own price target on Alamar shares to $32 from $28, according to recent analyst commentary, reflecting growing confidence in the company's commercial trajectory even as the stock's rapid appreciation has occasionally outpaced individual analyst targets. Founded in 2018 and based in Fremont, California, Alamar Biosciences describes itself as a leader in precision proteomics dedicated to enabling the earliest possible detection of disease. The company's core technology, known as NULISA, stands for Nucleic Acid Linked Immuno-Sandwich Assay, an ultrasensitive protein detection method the company has paired with its proprietary ARGO HT instrument to offer researchers and, eventually, clinicians a highly automated platform for identifying disease-related protein biomarkers at extremely low concentrations. The company has said it intends to pursue a path toward clinical diagnostic applications for the platform, with an FDA submission for an in vitro diagnostic system expected as soon as next year, part of a broader roadmap aimed at moving the technology beyond research use and into standard clinical practice. That platform has found particularly strong early adoption within neurology and Alzheimer's disease research. In August, Alamar announced an expanded global partnership with the Alzheimer's Disease Data Initiative and Gates Ventures, under which a national-scale research initiative will use the company's NULISAseq Neuro 220 panel to profile approximately 21,000 plasma samples collected from 10,000 participants with Alzheimer's disease and related dementias. The company also launched its NULISAseq Immune 340 Panel in late July, expanding its product portfolio to offer more comprehensive profiling of the immune proteome for researchers studying immune-related conditions. Alamar's most recent quarterly results, reported August 10 alongside updated full-year 2026 revenue guidance, showed a sharp rise in revenue driven by accelerating demand for the company's consumable testing products, alongside gross margin expansion the company attributed to improving operational scale. Those results helped fuel renewed investor interest in the stock even as the company continues to operate at a net loss typical of early-stage life sciences companies still investing heavily in research, development and commercial expansion. The company presented at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, just days before Thursday's sharp share price advance, an appearance that gave company executives an additional platform to update institutional investors on Alamar's commercial progress and regulatory roadmap heading into the final months of the year. Recent insider transactions at the company have also drawn attention amid the stock's rally. Regulatory filings show General Counsel John Brottem received a restricted stock unit award and stock option grant on September 14, while newly appointed director Robert Ragusa, who joined Alamar's board on September 1 and was named to the company's Audit, Compensation, and Nominating and Corporate Governance Committees, received his own equity grants tied to his board appointment. Such routine compensation-related filings are common at newly public companies and do not typically reflect open-market buying or selling activity by company insiders. Alamar's market capitalization has climbed to approximately $1.94 billion in recent weeks, reflecting the stock's substantial appreciation since its spring IPO. Trading volume in the stock has remained well above its historical daily average in recent sessions, a pattern often associated with heightened investor attention following news-driven catalysts, though no single company-specific announcement dated to Thursday's session had been identified as the direct trigger for the day's sharp gain as of the time of this report. With Alamar continuing to expand its commercial partnerships in neurology and immunology research while advancing toward its stated goal of regulatory clearance for clinical diagnostic use, investors are likely to watch closely for further updates on the company's progress toward that FDA submission, along with continued commercial traction for its expanding panel of research products, as key indicators of whether the stock's recent rally can be sustained in the months ahead. MEET IBT NEWS FROM BELOW CHANNELS
Alamar Biosciences to participate in Morgan Stanley 24th Annual Global Healthcare Conference. FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) - Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Alamar Biosciences' management is scheduled to participate in a fireside chat on Tuesday, September 15, at 4:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the session on the "Investors" section of the company website at investors.alamarbio.com. About Alamar Biosciences, Inc. Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA(TM) technology and the ARGO(TM) HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as "Precision Proteomics," and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. Investor contact: Media contact:
Alamar Biosciences reported a second-quarter loss of $13.2 million, or 22 cents per share, beating analyst expectations of a 36-cent loss. The Fremont, California-based proteomics company posted revenue of $29.4 million for the period. Proteomics involves the study and measurement of proteins in the body. Alamar forecasts full-year revenue between $116 million and $120 million. The results exceeded Wall Street projections based on estimates from three analysts surveyed by Zacks Investment Research.
Alamar Biosciences Q2 earnings call highlights. August 10, 2026 Key points. * Revenue surged 82% year over year to $29.4 million in Q2 2026, driven primarily by consumables revenue, which rose 147% to $15.5 million. Gross margin reached a record 60% as higher-margin consumables and manufacturing efficiencies improved the product mix. * Alamar ended the quarter with $256.3 million in cash, investments and restricted cash after raising $197.8 million in net IPO proceeds, although its operating loss widened to $13.5 million amid increased research, sales and public-company expenses. * Management forecast 2026 revenue of $116 million to $120 million and plans to add at least 100 instruments while expanding its neurology and immune panel offerings. Longer-term priorities include an FDA submission for the ARGO HT DX clinical instrument and additional diagnostic partnerships. * MarketBeat previews top five stocks to own in September. Alamar Biosciences NASDAQ: ALMR reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company's first earnings call since completing its April initial public offering. Chief Executive Officer Yuling Luo said the quarter reflected continued adoption of the company's precision proteomics platform, which combines ultra-high sensitivity, specificity, multiplexing, dynamic range and automation. The company's ARGO HT platform is used in research applications, with an initial focus on neurology and inflammation. "Q2 2026 was a strong quarter that reflects the momentum of our business," Luo said. Consumable revenue represented 53% of total revenue and grew 147% year over year, while the company achieved a 60% gross margin for the first time. Revenue growth driven by consumables. Chief Financial Officer Justin McAnear said consumables revenue totaled $15.5 million in the quarter, driven by demand for multiplex panel kits as the installed base expanded. Instrument revenue increased 35% to $7.8 million, while service and other revenue rose 49% to $6.2 million. Service revenue includes the company's Technology Access Program, or TAP, as well as maintenance contracts. McAnear said TAP is intended to support customer acquisition, custom assay development and product beta testing rather than operate as a long-term service business. The Q2 increase was primarily attributable to larger custom assay development projects. During the question-and-answer session, President Tod White said TAP activity was higher than management had expected in the second quarter and should continue into the third quarter, though not at the Q2 level. He characterized the service pipeline as a potential leading indicator of future instrument and consumable demand. Geographically, the Americas accounted for 69% of second-quarter revenue, followed by Europe, the Middle East and Africa at 22% and Asia-Pacific at 9%. Academic and research institutions generated 52% of revenue, biopharmaceutical customers contributed 42%, and distributors represented the remaining 6%. Luo said both academic and biopharmaceutical customer segments experienced strong growth during the quarter. White added that most year-to-date instrument placements have gone to new customers, although existing customers have also been adding instruments and, in some cases, expanding platform use to additional sites. Margins improve as product mix shifts. Gross profit increased to $17.7 million from $8.6 million a year earlier, and gross margin improved to 60% from 53%. McAnear attributed the expansion to manufacturing efficiencies as consumable production scaled and to a greater revenue contribution from consumables, which carry higher margins than instruments. Discover more EV Market Report Stock Average Calculator MarketBeat Research Tools White said gross margin could fluctuate in the mid-to-high 50% range in the near term, depending on the mix of instruments, consumables and services. However, he said management expects margins to trend higher over time as consumables become a larger share of revenue. Operating expenses rose to $31.2 million from $16.5 million in the prior-year quarter. Research and development expense increased 55% to $13.8 million, reflecting laboratory supply and personnel costs associated with expanding the company's panel menu. Selling, general and administrative expense rose 129% to $17.4 million, driven by personnel and higher legal and accounting expenses associated with becoming a public company. Alamar reported a $13.5 million operating loss, compared with a $7.9 million loss a year earlier. Net loss was $13.2 million, versus $7 million in the second quarter of 2025. The company recorded $3.3 million in stock-based compensation during the quarter. As of June 30, Alamar had $256.3 million in cash equivalents, short-term investments and restricted cash. McAnear said the April IPO generated $197.8 million in net proceeds. The company also refinanced its debt facility with SVB First Citizens Bank, establishing a revolving credit facility with $60 million available at closing and a further $40 million uncommitted accordion. New panels and large neurology studies. Alamar launched the NULISAseq Neuro 220 Panel in March and introduced a multiplex blood-based immunoassay for eMTBR-Tau in July. Luo said eMTBR-Tau is designed to measure tau tangle burden from blood samples and can be multiplexed with other neurodegeneration and neuroinflammation biomarkers. The company also launched the NULISAseq Immune 340 Panel, which measures approximately 340 immune-related proteins from a single blood sample, and introduced a dried blood spot extraction kit designed to make home-collected fingerstick samples compatible with its platform. Luo said Alamar added more than 40 publications and preprints during the quarter, bringing its cumulative total to 165. At the Alzheimer's Association International Conference, the company counted more than 140 posters and presentations featuring NULISA technology, a fourfold increase from the prior year. The company also expanded its partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to add profiling of 86,000 plasma samples using the Neuro 220 Panel. The expanded agreement includes a national-scale initiative involving approximately 21,000 plasma samples from 10,000 Alzheimer's Disease Research Center participants. The combined dataset is expected to include more than 140,000 samples and be completed in 2027. 2026 outlook and clinical strategy. Alamar forecast full-year 2026 revenue of $116 million to $120 million, representing 59% annual growth at the midpoint. Management expects third-quarter revenue to increase modestly sequentially from the second quarter, which White described as low-single-digit sequential growth. For the full year, the company aims to add at least 100 instruments to its installed base and maintain annual per-instrument pull-through above $400,000. White said quarterly pull-through can fluctuate as new instruments are placed, and the company plans to report installed-base and average pull-through metrics annually. Looking toward 2027, Alamar plans to launch a multiplex panel targeting another disease area, submit its ARGO HT DX clinical instrument for FDA marketing authorization, and establish partnerships to support diagnostic test development. The company said it intends to invest IPO proceeds in commercial expansion, manufacturing capacity and research and development. About Alamar Biosciences (NASDAQ:ALMR). Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Alamar Biosciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alamar Biosciences wasn't on the list. While Alamar Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.